Centiva Capital’s Ginkgo Bioworks DNA Stock Holding History

Centiva Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100	Closed	-$33K	–	1671
2021 Q4	$33K	Buy	+100	New	+$47.5K	﹤0.01%	1096

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Centiva Capital's DNA Position: Q3 2024 in Review

Centiva Capital sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 18,861 shares — an estimated $252K sold.

Centiva Capital first reported a position in DNA in Q2 2022 and held it in 3 quarters. The position peaked at $252K in Q2 2024. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

Centiva Capital reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 18,861 Ginkgo Bioworks shares in Q3 2024, an estimated $252K.
Centiva Capital first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 3 quarters.
Centiva Capital's Ginkgo Bioworks position peaked at $252K in Q2 2024.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.